Compare MSEX & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSEX | ESPR |
|---|---|---|
| Founded | 1897 | 2008 |
| Country | United States | United States |
| Employees | 395 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.5M | 816.9M |
| IPO Year | N/A | 2013 |
| Metric | MSEX | ESPR |
|---|---|---|
| Price | $57.66 | $3.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $61.33 | $8.75 |
| AVG Volume (30 Days) | 153.9K | ★ 9.7M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | $10.60 | N/A |
| Revenue Next Year | $10.94 | $12.81 |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $44.94 | $1.10 |
| 52 Week High | $62.18 | $4.18 |
| Indicator | MSEX | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 73.53 | 64.86 |
| Support Level | $49.91 | $3.13 |
| Resistance Level | $62.18 | $3.18 |
| Average True Range (ATR) | 1.20 | 0.02 |
| MACD | 0.47 | -0.01 |
| Stochastic Oscillator | 93.28 | 75.00 |
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.